Halozyme delivers record Q2, raises 2026 guidance and expands ENHANZE partnerships
Aug 6, 2026, 4:04 PM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting
The quarter beat and 2026 guidance raise de-risk near-term upside. The rapid expansion of ENHANZE collaborations across top-tier pharma (Vertex, Incyte, GSK, Janssen) implies a higher baseline royalty trajectory and optionality from new targets, consistent with past HALO post-earnings rallies. The 2028 buyback and cash-return plan further supports multiple expansion.
AI summary
What happened, with direct paths to the underlying reporting
Halozyme posted record Q2 results with total revenue of $481 million, up 48% YoY, and royalty revenue of $307.7 million, up 50%. The company raised full-year guidance to $1.835–$1.910 billion in revenue and $1.225–$1.280 billion in EBITDA, underscoring durable ENHANZE royalties. Expansion via five new ENHANZE/Hypercon collaborations and a robust share-repurchase program reinforce long-term growth and capital-return upside.
Halozyme Q2 revenue: $481M, up 48% YoY; royalty revenue $308M, up 50% YoY.
Five ENHANZE/Hypercon collaborations signed YTD 2026, including Vertex and Incyte.
Share repurchase: $333M bought in 2Q at $69.30; new program up to $1B by 2028.
Partner activity highlights: Janssen, GSK, Vertex, Incyte, Viatris and argenx active across ENHANZE.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
Halozyme proposed a €2 billion cash takeover for Evotec. The deal aims to create a leading pharma services company. Combined revenue is projected to reach $2 billion by 2025. Halo…
